metronidazole has been researched along with Abdominal Abscess in 49 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Abdominal Abscess: An abscess located in the abdominal cavity, i.e., the cavity between the diaphragm above and the pelvis below. (From Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the safety and efficacy of cefepime hydrochloride plus metronidazole vs the combination of imipenem and cilastatin sodium in the treatment of complicated intra-abdominal infections in adult patients." | 9.08 | A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. ( Barie, PS; Baumgartner, TF; Dellinger, EP; Rotstein, OD; Solomkin, JS; Vogel, SB; Yang, JY, 1997) |
| "Recent studies are discordant regarding postoperative use of piperacillin/tazobactam (PT) versus ceftriaxone/metronidazole (CM) for pediatric complicated appendicitis." | 8.31 | Postoperative Antibiotics for Complicated Appendicitis in Children: Piperacillin/Tazobactam Versus Ceftriaxone with Metronidazole. ( Abdullah, F; Alayleh, A; Carter, M; De Boer, C; Goldstein, SD; Hu, A; Linton, S; Pitt, JB; Raval, M; Zeineddin, S, 2023) |
| "In a prospective study, 182 consecutive patients were included for the treatment of intraabdominal sepsis with adjuvant metronidazole lavage that was carried out at the end of the operative procedures." | 7.69 | Efficacy of metronidazole lavage in treatment of intraperitoneal sepsis. A prospective study. ( Saha, SK, 1996) |
| " The most common treatment-related adverse event was diarrhea (23." | 6.80 | Efficacy and safety of metronidazole injection for the treatment of infectious peritonitis, abdominal abscess and pelvic inflammatory diseases in Japan. ( Matsumizu, M; Mikamo, H; Nagashima, M; Nakazuru, Y, 2015) |
| "To evaluate the safety and efficacy of cefepime hydrochloride plus metronidazole vs the combination of imipenem and cilastatin sodium in the treatment of complicated intra-abdominal infections in adult patients." | 5.08 | A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. ( Barie, PS; Baumgartner, TF; Dellinger, EP; Rotstein, OD; Solomkin, JS; Vogel, SB; Yang, JY, 1997) |
| "Recent studies are discordant regarding postoperative use of piperacillin/tazobactam (PT) versus ceftriaxone/metronidazole (CM) for pediatric complicated appendicitis." | 4.31 | Postoperative Antibiotics for Complicated Appendicitis in Children: Piperacillin/Tazobactam Versus Ceftriaxone with Metronidazole. ( Abdullah, F; Alayleh, A; Carter, M; De Boer, C; Goldstein, SD; Hu, A; Linton, S; Pitt, JB; Raval, M; Zeineddin, S, 2023) |
| "Metronidazole is commonly prescribed for intra-abdominal infections." | 4.02 | Improving metronidazole prescription practices in surgical patients: a full cycle audit. ( Sgrò, A; Wu, DA; Yalamarthi, S, 2021) |
| "In complicated appendicitis, empirical perioperative addition of gentamycin to ceftriaxone and metronidazole did not reduce the risk of developing intra-abdominal abscess, compared to changing antibiotics on clinical grounds." | 3.74 | Antibiotics and postoperative abscesses in complicated appendicitis: is there any association? ( Chan, TK; Chui, CH; Jacobsen, AS; Ong, CP, 2008) |
| "In a prospective study, 182 consecutive patients were included for the treatment of intraabdominal sepsis with adjuvant metronidazole lavage that was carried out at the end of the operative procedures." | 3.69 | Efficacy of metronidazole lavage in treatment of intraperitoneal sepsis. A prospective study. ( Saha, SK, 1996) |
| " The most common treatment-related adverse event was diarrhea (23." | 2.80 | Efficacy and safety of metronidazole injection for the treatment of infectious peritonitis, abdominal abscess and pelvic inflammatory diseases in Japan. ( Matsumizu, M; Mikamo, H; Nagashima, M; Nakazuru, Y, 2015) |
| " All patients were treated with once-daily dosing of ceftriaxone and metronidazole throughout their course." | 2.80 | Saline vs Tissue Plasminogen Activator Irrigations after Drain Placement for Appendicitis-Associated Abscess: A Prospective Randomized Trial. ( Adibe, OO; Cully, B; Holcomb, GW; Reading, B; Rivard, DC; Shah, SR; Sharp, SW; St Peter, SD, 2015) |
| " Therefore, a correct dosing regimen for the time-dependent molecules (i." | 2.44 | [Pharmacological rationale for choice of antibiotics for intraabdominal infections]. ( Mazzei, T; Novelli, A, 2008) |
| "When an abdominal abscess is seen in an immunocompromised patient such as a cirrhotic patient, amoeba infection should be considered as a possible diagnosis." | 1.62 | An encapsulated bulky abdominal abscess due to amoeba. ( Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Iritani, S; Kajiwara, A; Kawamura, Y; Kobayashi, M; Kumada, H; Muraishi, N; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yamashige, D, 2021) |
| "Metronidazole was administered orally from 3 days after admission." | 1.38 | [A case of fulminant amoebic colitis with an abscess in the abdominal cavity rescued by conservative management]. ( Domon, K; Fujii, T; Furuhata, T; Hoteya, S; Iizuka, T; Kaise, M; Kikuchi, D; Matoba, S; Matsui, A; Mitani, T; Nakamura, M; Nomura, K; Odagiri, H; Ogawa, O; Yamada, A; Yamashita, S, 2012) |
| "For optimal treatment, abdominal abscesses require prompt drainage and properly selected antibiotics at adequate doses." | 1.37 | Impact of evaluating antibiotic concentrations in abdominal abscesses percutaneously drained. ( Barshikar, S; Baylor, AE; Dolman, HS; Glowniak, J; Hong, K; Lavery, T; Nailor, M; Singla, R; Stassinopoulus, J; Tyburski, JG; Wilson, RF; Zimmerman, LH, 2011) |
| "Peritonitis was induced via intra-abdominal injection of a faeces and bacteria mixture in male Wistar rats." | 1.35 | Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis. ( Bleichrodt, RP; Buyne, OR; Hendriks, T; van Goor, H; Verweij, PE, 2008) |
| "Outcome data such as recurrence and intractability, and clinical features were retrospectively analysed." | 1.33 | Nonsurgical treatment of abdominal or pelvic abscess in consecutive patients with Crohn's disease. ( Chang, DK; Kim, JH; Kim, JJ; Kim, YH; Lee, H; Paik, SW; Rhee, JC; Rhee, PL; Son, HJ, 2006) |
| "metronidazole (MTR) was compared with i." | 1.32 | Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment ( Asimakopoulos, C; Bassaris, H; Harlaftis, N; Karravias, D; Kolaras, P; Nikolaidis, P; Skoutelis, A; Starakis, I, 2003) |
| "A patient had Crohn's disease in relapse with multiple small bowel fistulae and mesenteric abscesses." | 1.30 | Relative sensitivity of Tc-99m WBC versus In-111 WBC in a patient with Crohn's disease on steroids. ( Broekelschen, P; Challa, S; Lyons, KP; Milne, N, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (16.33) | 18.2507 |
| 2000's | 22 (44.90) | 29.6817 |
| 2010's | 15 (30.61) | 24.3611 |
| 2020's | 4 (8.16) | 2.80 |
| Authors | Studies |
|---|---|
| Zeineddin, S | 1 |
| Pitt, JB | 1 |
| Linton, S | 1 |
| De Boer, C | 1 |
| Hu, A | 1 |
| Carter, M | 1 |
| Alayleh, A | 1 |
| Abdullah, F | 1 |
| Raval, M | 1 |
| Goldstein, SD | 1 |
| Arezzo, A | 1 |
| Nicotera, A | 1 |
| Bonomo, LD | 1 |
| Olandese, F | 1 |
| Veglia, S | 1 |
| Ferguglia, A | 1 |
| Pentassuglia, G | 1 |
| Mingrone, G | 1 |
| Morino, M | 1 |
| Iritani, S | 1 |
| Kawamura, Y | 1 |
| Yamashige, D | 1 |
| Muraishi, N | 1 |
| Kajiwara, A | 1 |
| Fujiyama, S | 1 |
| Sezaki, H | 1 |
| Hosaka, T | 1 |
| Akuta, N | 1 |
| Kobayashi, M | 2 |
| Saitoh, S | 1 |
| Suzuki, F | 1 |
| Arase, Y | 1 |
| Ikeda, K | 1 |
| Suzuki, Y | 1 |
| Kumada, H | 1 |
| Sgrò, A | 1 |
| Wu, DA | 1 |
| Yalamarthi, S | 1 |
| Ueno, T | 1 |
| Ito, M | 1 |
| Arai, A | 1 |
| Suzuki, C | 1 |
| Tomiyama, M | 1 |
| Iio, K | 1 |
| Ariyama, Y | 1 |
| Tomita, H | 1 |
| Sakakibara, H | 1 |
| Hataya, H | 1 |
| Erginel, B | 1 |
| Oksüz, L | 1 |
| Erginel, T | 1 |
| Gün, F | 1 |
| Yanar, F | 1 |
| Gürler, N | 1 |
| Salman, T | 1 |
| Celik, A | 1 |
| Van den Berg, SA | 1 |
| Verwer, PE | 1 |
| Idema, RN | 1 |
| Van Guldener, C | 1 |
| Mikamo, H | 1 |
| Matsumizu, M | 1 |
| Nakazuru, Y | 1 |
| Nagashima, M | 1 |
| St Peter, SD | 1 |
| Shah, SR | 1 |
| Adibe, OO | 1 |
| Sharp, SW | 1 |
| Reading, B | 1 |
| Cully, B | 1 |
| Holcomb, GW | 1 |
| Rivard, DC | 1 |
| Vahdad, MR | 1 |
| Nissen, M | 1 |
| Semaan, A | 1 |
| Klein, T | 1 |
| Palade, E | 1 |
| Boemers, T | 1 |
| Foroutan, HR | 1 |
| Troebs, RB | 1 |
| Cernaianu, G | 1 |
| Hurst, AL | 1 |
| Olson, D | 1 |
| Somme, S | 1 |
| Child, J | 1 |
| Pyle, L | 1 |
| Ranade, D | 1 |
| Stamatoiu, A | 1 |
| Crombleholme, T | 1 |
| Parker, SK | 1 |
| Kuriyama, A | 1 |
| Otte, E | 1 |
| Nielsen, HL | 1 |
| Hasman, H | 1 |
| Fuglsang-Damgaard, D | 1 |
| Paladino, JA | 1 |
| Gilliland-Johnson, KK | 1 |
| Adelman, MH | 1 |
| Cohn, SM | 2 |
| Chandra, A | 1 |
| Dhar, P | 1 |
| Dharap, S | 1 |
| Goel, A | 1 |
| Gupta, R | 1 |
| Hardikar, JV | 1 |
| Kapoor, VK | 1 |
| Mathur, AK | 1 |
| Modi, P | 1 |
| Narwaria, M | 1 |
| Ramesh, MK | 1 |
| Ramesh, H | 1 |
| Sastry, RA | 1 |
| Shah, S | 1 |
| Virk, S | 1 |
| Sudheer, OV | 1 |
| Sreevathsa, MR | 1 |
| Varshney, S | 1 |
| Kochhar, P | 1 |
| Somasundaram, S | 1 |
| Desai, C | 1 |
| Schou, M | 1 |
| Buyne, OR | 1 |
| Bleichrodt, RP | 1 |
| van Goor, H | 1 |
| Verweij, PE | 1 |
| Hendriks, T | 1 |
| Ong, CP | 1 |
| Chan, TK | 1 |
| Chui, CH | 1 |
| Jacobsen, AS | 1 |
| Tuduri, I | 1 |
| Duggal, S | 1 |
| Mahajan, RK | 1 |
| Biswas, NK | 1 |
| Chandel, DS | 1 |
| Duggal, N | 1 |
| Hans, C | 1 |
| Weiss, G | 1 |
| Reimnitz, P | 1 |
| Hampel, B | 1 |
| Muehlhofer, E | 1 |
| Lippert, H | 1 |
| Zimmerman, LH | 1 |
| Tyburski, JG | 1 |
| Glowniak, J | 1 |
| Singla, R | 1 |
| Lavery, T | 1 |
| Nailor, M | 1 |
| Stassinopoulus, J | 1 |
| Hong, K | 1 |
| Barshikar, S | 1 |
| Dolman, HS | 1 |
| Baylor, AE | 1 |
| Wilson, RF | 1 |
| Khodakaram, K | 1 |
| Barmano, N | 1 |
| Leeuwenburgh, MM | 1 |
| Monpellier, V | 1 |
| Vlaminckx, BJ | 1 |
| Go, PM | 1 |
| Matsui, A | 1 |
| Nomura, K | 1 |
| Odagiri, H | 1 |
| Yamada, A | 1 |
| Domon, K | 1 |
| Yamashita, S | 1 |
| Furuhata, T | 1 |
| Kikuchi, D | 1 |
| Nakamura, M | 1 |
| Mitani, T | 1 |
| Ogawa, O | 1 |
| Iizuka, T | 1 |
| Hoteya, S | 1 |
| Kaise, M | 1 |
| Matoba, S | 1 |
| Fujii, T | 1 |
| Johnston, MJ | 1 |
| Nkwam, N | 1 |
| Eaton, J | 1 |
| Starakis, I | 1 |
| Karravias, D | 1 |
| Asimakopoulos, C | 1 |
| Kolaras, P | 1 |
| Nikolaidis, P | 3 |
| Harlaftis, N | 1 |
| Skoutelis, A | 1 |
| Bassaris, H | 2 |
| Emil, S | 1 |
| Laberge, JM | 1 |
| Mikhail, P | 1 |
| Baican, L | 1 |
| Flageole, H | 1 |
| Nguyen, L | 1 |
| Shaw, K | 1 |
| Heaney, CJ | 1 |
| Campeau, NG | 1 |
| Lindell, EP | 1 |
| Thadepalli, H | 2 |
| Chuah, SK | 2 |
| Gollapudi, S | 2 |
| Vidad, A | 1 |
| Calvert, LD | 1 |
| Collins, M | 1 |
| Bateman, JR | 1 |
| Lee, H | 1 |
| Kim, YH | 1 |
| Kim, JH | 1 |
| Chang, DK | 1 |
| Son, HJ | 1 |
| Rhee, PL | 1 |
| Kim, JJ | 1 |
| Paik, SW | 1 |
| Rhee, JC | 1 |
| Mogg, TD | 1 |
| Rutherford, DJ | 1 |
| Wacha, H | 1 |
| Warren, B | 1 |
| Forgues, D | 1 |
| Habbig, S | 1 |
| Diallo, AF | 1 |
| Kalfa, N | 1 |
| Lopez, M | 1 |
| Allal, H | 1 |
| Guibal, MP | 1 |
| Sabatier-Laval, E | 1 |
| Galifer, RB | 1 |
| Khan, MN | 1 |
| Vidya, R | 1 |
| Lee, RE | 1 |
| Ea, HK | 1 |
| Zeller, V | 1 |
| Chicheportiche, V | 1 |
| Desplaces, N | 1 |
| Ziza, JM | 1 |
| Mazzei, T | 1 |
| Novelli, A | 1 |
| Saha, SK | 1 |
| Angerås, MH | 1 |
| Darle, N | 1 |
| Hamnström, K | 1 |
| Ekelund, M | 1 |
| Engström, L | 1 |
| Takala, J | 1 |
| Viste, A | 1 |
| Holme, JB | 1 |
| Lyons, KP | 2 |
| Challa, S | 2 |
| Broekelschen, P | 2 |
| Milne, N | 2 |
| Cohen, SE | 1 |
| Ligumsky, M | 1 |
| Bar-Ziv, J | 1 |
| Safadi, R | 1 |
| Barie, PS | 1 |
| Vogel, SB | 1 |
| Dellinger, EP | 1 |
| Rotstein, OD | 1 |
| Solomkin, JS | 1 |
| Yang, JY | 1 |
| Baumgartner, TF | 1 |
| Sitges-Serra, A | 1 |
| Guirao, X | 1 |
| Díaz, J | 1 |
| Azanza, R | 1 |
| Rodríguez Noriega, A | 1 |
| Lizasoaín, M | 1 |
| Jover, JM | 1 |
| Moreno Azcoita, M | 1 |
| Caínzos, M | 1 |
| Ohlin, B | 1 |
| Cederberg, A | 1 |
| Forssell, H | 1 |
| Solhaug, JH | 1 |
| Tveit, E | 1 |
| Lipsett, PA | 1 |
| Buchman, TG | 1 |
| Cheadle, WG | 1 |
| Milsom, JW | 1 |
| O'Marro, S | 1 |
| Yellin, AE | 1 |
| Jungerwirth, S | 1 |
| Rochefort, EV | 1 |
| Haverstock, DC | 1 |
| Kowalsky, SF | 1 |
| Maltezou, HC | 1 |
| Lebesii, E | 1 |
| Dimitriou, L | 1 |
| Androulakakis, E | 1 |
| Kafetzis, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone[NCT01473836] | Phase 3 | 38 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Single Incision Versus Standard Laparoscopic Appendectomy for Non-Perforated Appendicitis[NCT00981136] | 360 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| A Randomized, Open Label, Multicentre Phase Iv Study To Evaluate The Efficacy And Safety Of Magnex (Cefoperazone-Sulbactam) In Comparison With Ceftazidime Plus Amikacin And Metronidazole In The Treatment Of Intra-Abdominal Infections[NCT00360607] | Phase 4 | 307 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Antibiotic Irrigations for Intra-Abdominal Drains[NCT03476941] | Phase 2 | 50 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The appropriateness of treatment continuation was evaluated on Day 4 by the investigator as continuation, discontinuation or indeterminate based on the clinical response. The percentage of participants was calculated from the following formula; number of participants assessed as continuation over total number of participants that excluding ones assessed as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to Day 4
| Intervention | percentage of participants (Number) |
|---|---|
| Metronidazole/Ceftriaxone | 100.0 |
"Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the data review committee, at Day 4, at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, number of participants with bacteria eradication, presumed eradication or colonization over total number of participants that excluding ones evaluated as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to Day 4, EOT (up to 14 days), TOC
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 4 | End of Treatment | Test of Cure | |
| Metronidazole/Ceftriaxone | 100.0 | 100.0 | 100.0 |
"Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the investigator at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, number of participants with bacteria eradication, presumed eradication or colonization over total number of participants that excluding ones evaluated as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to Day 4, EOT (up to 14 days), TOC
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 4 | EOT | TOC | |
| Metronidazole/Ceftriaxone | 100.0 | 100.0 | 100.0 |
"Clinical response was evaluated by the data review committee as effective (cured or improved), ineffective (not meeting effective criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; number of participants evaluated as effective over total number of participants that excluding ones evaluated as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to EOT (up to 14 days), TOC
| Intervention | percentage of participants (Number) | |
|---|---|---|
| End of Treatment (n=30) | Test of Cure (n=30) | |
| Metronidazole/Ceftriaxone | 96.6 | 96.7 |
"Clinical response was evaluated by the investigator as effective (cured or improved), ineffective (not meeting effective criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; number of participants evaluated as effective over total number of participants that excluding ones evaluated as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to EOT (up to 14 days), TOC
| Intervention | percentage of participants (Number) | |
|---|---|---|
| End of Treatment (n=30) | Test of Cure (n=29) | |
| Metronidazole/Ceftriaxone | 96.7 | 100.0 |
1 review available for metronidazole and Abdominal Abscess
| Article | Year |
|---|---|
[Pharmacological rationale for choice of antibiotics for intraabdominal infections].
Topics: Abdominal Abscess; Acetamides; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; beta-L | 2008 |
12 trials available for metronidazole and Abdominal Abscess
| Article | Year |
|---|---|
Efficacy and safety of metronidazole injection for the treatment of infectious peritonitis, abdominal abscess and pelvic inflammatory diseases in Japan.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Anti-Infective Agents; Bacteria; Female; Humans; Japan; | 2015 |
Saline vs Tissue Plasminogen Activator Irrigations after Drain Placement for Appendicitis-Associated Abscess: A Prospective Randomized Trial.
Topics: Abdominal Abscess; Adolescent; Anti-Infective Agents; Appendicitis; Ceftriaxone; Child; Child, Presc | 2015 |
Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.
Topics: Abdominal Abscess; Adult; Aged; Anti-Bacterial Agents; Appendicitis; Ciprofloxacin; Cost-Benefit Ana | 2008 |
Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Cefoperazone; Ceftazidi | 2008 |
Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
Topics: Abdominal Abscess; Administration, Oral; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; | 2009 |
Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections.
Topics: Abdomen; Abdominal Abscess; Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Cipro | 2006 |
A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections.
Topics: Abdomen; Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Cefuro | 1996 |
A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group.
Topics: Abdomen; Abdominal Abscess; Adult; Aged; Antitrichomonal Agents; Appendicitis; Cefepime; Cephalospor | 1997 |
[Prospective randomized trial of meropenem versus cefotaxime and metronidazole in the treatment of intraabdominal infections].
Topics: Abdomen; Abdominal Abscess; Adult; Aged; Bacterial Infections; Cefotaxime; Drug Therapy, Combination | 1998 |
Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections.
Topics: Abdominal Abscess; Appendicitis; Bacterial Infections; beta-Lactamase Inhibitors; Cefuroxime; Drug T | 1999 |
Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections.
Topics: Abdomen; Abdominal Abscess; Administration, Oral; Anti-Infective Agents; Appendicitis; Bacterial Inf | 2000 |
Piperacillin/Tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery.
Topics: Abdominal Abscess; Adolescent; Appendicitis; Bacterial Infections; Cefotaxime; Child; Child, Prescho | 2001 |
36 other studies available for metronidazole and Abdominal Abscess
| Article | Year |
|---|---|
Postoperative Antibiotics for Complicated Appendicitis in Children: Piperacillin/Tazobactam Versus Ceftriaxone with Metronidazole.
Topics: Abdominal Abscess; Abscess; Adolescent; Anti-Bacterial Agents; Appendectomy; Appendicitis; Ceftriaxo | 2023 |
Outcomes of surgical treatment of diverticular abscesses after failure of antibiotic therapy.
Topics: Abdominal Abscess; Abscess; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ci | 2023 |
An encapsulated bulky abdominal abscess due to amoeba.
Topics: Abdominal Abscess; Amoeba; Entamoeba histolytica; Entamoebiasis; Humans; Liver Abscess, Amebic; Metr | 2021 |
Improving metronidazole prescription practices in surgical patients: a full cycle audit.
Topics: Abdominal Abscess; Administration, Oral; Aged; Anti-Bacterial Agents; Drug Utilization; Female; Heal | 2021 |
Convulsive seizures caused by metronidazole-induced encephalopathy.
Topics: Abdominal Abscess; Anti-Infective Agents; Brain Diseases; Cerebellar Nuclei; Humans; Magnetic Resona | 2019 |
Secondary haemophagocytic lymphohistiocytosis associated with metronidazole.
Topics: Abdominal Abscess; Appendectomy; Appendicitis; Child; Dexamethasone; Female; Follow-Up Studies; Huma | 2019 |
Effects of tissue plasminogen activator in experimentally induced peritonitis.
Topics: Abdominal Abscess; Animals; Anti-Bacterial Agents; Ascitic Fluid; Ceftriaxone; Cytokines; Disease Mo | 2014 |
Transient cefuroxime/metronidazole treatment induced factor V antibodies.
Topics: Abdominal Abscess; Adult; Anti-Bacterial Agents; Antibodies; Blood Coagulation Disorders; Cefuroxime | 2014 |
Experiences with LESS-appendectomy in Children.
Topics: Abdominal Abscess; Adolescent; Anti-Bacterial Agents; Appendectomy; Appendicitis; Cefuroxime; Child; | 2016 |
Once-Daily Ceftriaxone Plus Metronidazole Versus Ertapenem and/or Cefoxitin for Pediatric Appendicitis.
Topics: Abdominal Abscess; Adolescent; Appendectomy; Appendicitis; beta-Lactams; Cefoxitin; Ceftriaxone; Chi | 2017 |
Chestnut Sign: Metronidazole-Induced Encephalopathy.
Topics: Abdominal Abscess; Aged; Anti-Bacterial Agents; Ataxia; Brain Diseases; Ciprofloxacin; Depression; D | 2017 |
First report of metronidazole resistant, nimD-positive, Bacteroides stercoris isolated from an abdominal abscess in a 70-year-old woman.
Topics: Abdominal Abscess; Aged; Anti-Bacterial Agents; Bacterial Proteins; Bacteroides; Bacteroides Infecti | 2017 |
Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis.
Topics: Abdominal Abscess; Animals; Anti-Bacterial Agents; Ceftriaxone; Debridement; Fibrinolytic Agents; Ma | 2008 |
Antibiotics and postoperative abscesses in complicated appendicitis: is there any association?
Topics: Abdominal Abscess; Anti-Bacterial Agents; Appendectomy; Appendicitis; Ceftriaxone; Child; Female; Hu | 2008 |
Considerations about the article by St. Peter "Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomised trial". J Pediatr Surg 2008;43:981-985.
Topics: Abdominal Abscess; Appendicitis; Cefoxitin; Ceftriaxone; Cefuroxime; Child; Community-Acquired Infec | 2008 |
Splenic abscess due to Salmonella enterica Serotype typhi in a young adult.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Ceftriaxone; Humans; Male; Metronidazole; Ofloxacin; Salmo | 2008 |
Impact of evaluating antibiotic concentrations in abdominal abscesses percutaneously drained.
Topics: Abdominal Abscess; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Ciprofl | 2011 |
Uncommon reaction to a common prescription.
Topics: Abdominal Abscess; Anti-Infective Agents; Appendix; Brain; Delayed Diagnosis; Humans; Magnetic Reson | 2011 |
Streptococcus milleri in intraabdominal abscesses in children after appendectomy: incidence and course.
Topics: Abdominal Abscess; Adolescent; Anti-Bacterial Agents; Appendectomy; Appendicitis; Cefuroxime; Child; | 2012 |
[A case of fulminant amoebic colitis with an abscess in the abdominal cavity rescued by conservative management].
Topics: Abdominal Abscess; Aged; Drainage; Dysentery, Amebic; Humans; Male; Metronidazole | 2012 |
Large staghorn calculus presenting as a loin abscess and complicated by an abdominal aortic aneurysm.
Topics: Abdominal Abscess; Aged, 80 and over; Anti-Infective Agents; Aortic Aneurysm, Abdominal; Drainage; F | 2013 |
Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment
Topics: Abdominal Abscess; Adult; Aged; Bacterial Infections; Ceftriaxone; Ciprofloxacin; Double-Blind Metho | 2003 |
Appendicitis in children: a ten-year update of therapeutic recommendations.
Topics: Abdominal Abscess; Acute Disease; Adolescent; Ampicillin; Antibiotic Prophylaxis; Appendectomy; Appe | 2003 |
MR imaging and diffusion-weighted imaging changes in metronidazole (Flagyl)-induced cerebellar toxicity.
Topics: Abdominal Abscess; Abdominal Neoplasms; Aged; Amoxicillin; Anti-Infective Agents; Carcinoid Tumor; C | 2003 |
Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Topics: Abdominal Abscess; Animals; Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides | 2004 |
Efficacy of telithromycin in the treatment of experimental Bacteroides fragilis intraabdominal abscess in the senescent mice.
Topics: Abdominal Abscess; Age Factors; Aging; Animals; Anti-Bacterial Agents; Bacteroides fragilis; Bactero | 2004 |
Multiple abscesses caused by Gardnerella vaginalis in an immunocompetent man.
Topics: Abdominal Abscess; Bacterial Infections; Cefuroxime; Empyema, Pleural; Gardnerella vaginalis; Humans | 2005 |
Nonsurgical treatment of abdominal or pelvic abscess in consecutive patients with Crohn's disease.
Topics: Abdominal Abscess; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Bacterial Agents; Cephalos | 2006 |
Intra-abdominal abscess and peritonitis in an Appaloosa gelding.
Topics: Abdominal Abscess; Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Gentamic | 2006 |
Post-appendectomy intra-abdominal abscesses--can they successfully be managed with the sole use of antibiotic therapy?
Topics: Abdominal Abscess; Adolescent; Anti-Bacterial Agents; Appendectomy; Cefotaxime; Child; Child, Presch | 2007 |
Are routine peritoneal fluid cultures during appendicectomy justified?
Topics: Abdominal Abscess; Abdominal Cavity; Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxi | 2007 |
Polybacterial pyomyositis following laparoscopic colectomy for complicated diverticulosis.
Topics: Abdominal Abscess; Aged; Anti-Bacterial Agents; Ceftriaxone; Colectomy; Colon, Sigmoid; Diverticulit | 2007 |
Efficacy of metronidazole lavage in treatment of intraperitoneal sepsis. A prospective study.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infe | 1996 |
Relative sensitivity of Tc-99m WBC versus In-111 WBC in a patient with Crohn's disease on steroids.
Topics: Abdominal Abscess; Adult; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammator | 1997 |
Relative sensitivity of Tc-99m WBC versus In-111 WBC in a patient with Crohn disease and steroid use.
Topics: Abdominal Abscess; Adult; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammator | 1997 |
Conservative therapy in an ERCP-induced abdominal abscess.
Topics: Abdominal Abscess; Adult; Ampicillin; Aztreonam; Cholangiopancreatography, Endoscopic Retrograde; Ch | 1996 |